Ann Hynes
Stock Analyst at Mizuho
(5.00)
# 2
Out of 4,814 analysts
245
Total ratings
67.8%
Success rate
183.01%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group | Maintains: Outperform | $600 → $650 | $454.11 | +43.14% | 17 | Apr 9, 2025 | |
| DGX Quest Diagnostics | Maintains: Outperform | $178 → $189 | $163.77 | +15.41% | 14 | Apr 9, 2025 | |
| MOH Molina Healthcare | Maintains: Outperform | $376 → $400 | $322.37 | +24.08% | 8 | Apr 9, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $400 → $355 | $296.28 | +19.82% | 2 | Apr 9, 2025 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $210 | $143.91 | +45.92% | 11 | Apr 9, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $238 → $200 | $139.30 | +43.58% | 14 | Apr 9, 2025 | |
| HUM Humana | Maintains: Outperform | $305 → $316 | $264.38 | +19.53% | 8 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $12 → $10 | $5.28 | +89.39% | 2 | Apr 9, 2025 | |
| ELV Elevance Health | Maintains: Outperform | $455 → $505 | $424.53 | +18.96% | 4 | Apr 9, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $175 → $155 | $105.93 | +46.32% | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $76 | $67.28 | +12.96% | 10 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $12.51 | +43.88% | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $37 | $23.91 | +54.75% | 10 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $12.87 | +16.60% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $134.68 | -10.90% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $16.60 | +20.48% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $20.28 | +38.07% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 → $130 | $121.51 | +6.99% | 14 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $103.53 | -8.24% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $330.19 | +16.60% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $174.51 | +14.61% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $1.69 | +15,757.99% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $697.08 | -27.55% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $257 → $230 | $217.06 | +5.96% | 15 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $275 | $334.38 | -17.76% | 20 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $31 → $25 | $10.80 | +131.48% | 8 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $21.20 | +135.85% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $76 | $60.68 | +25.25% | 7 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $1.35 | +4,122.22% | 1 | Sep 21, 2017 |
UnitedHealth Group
Apr 9, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $454.11
Upside: +43.14%
Quest Diagnostics
Apr 9, 2025
Maintains: Outperform
Price Target: $178 → $189
Current: $163.77
Upside: +15.41%
Molina Healthcare
Apr 9, 2025
Maintains: Outperform
Price Target: $376 → $400
Current: $322.37
Upside: +24.08%
Medpace Holdings
Apr 9, 2025
Maintains: Outperform
Price Target: $400 → $355
Current: $296.28
Upside: +19.82%
IQVIA Holdings
Apr 9, 2025
Maintains: Outperform
Price Target: $242 → $210
Current: $143.91
Upside: +45.92%
ICON Public Limited Company
Apr 9, 2025
Maintains: Outperform
Price Target: $238 → $200
Current: $139.30
Upside: +43.58%
Humana
Apr 9, 2025
Maintains: Outperform
Price Target: $305 → $316
Current: $264.38
Upside: +19.53%
Fortrea Holdings
Apr 9, 2025
Maintains: Neutral
Price Target: $12 → $10
Current: $5.28
Upside: +89.39%
Elevance Health
Apr 9, 2025
Maintains: Outperform
Price Target: $455 → $505
Current: $424.53
Upside: +18.96%
Charles River Laboratories International
Apr 9, 2025
Maintains: Neutral
Price Target: $175 → $155
Current: $105.93
Upside: +46.32%
Apr 9, 2025
Maintains: Outperform
Price Target: $70 → $76
Current: $67.28
Upside: +12.96%
Apr 9, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $12.51
Upside: +43.88%
Mar 25, 2025
Maintains: Neutral
Price Target: $48 → $37
Current: $23.91
Upside: +54.75%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $12.87
Upside: +16.60%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $134.68
Upside: -10.90%
Nov 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $16.60
Upside: +20.48%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $20.28
Upside: +38.07%
May 1, 2024
Reiterates: Buy
Price Target: $118 → $130
Current: $121.51
Upside: +6.99%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $103.53
Upside: -8.24%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $330.19
Upside: +16.60%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $174.51
Upside: +14.61%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $1.69
Upside: +15,757.99%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $697.08
Upside: -27.55%
Oct 31, 2023
Maintains: Buy
Price Target: $257 → $230
Current: $217.06
Upside: +5.96%
Oct 25, 2023
Maintains: Buy
Price Target: $325 → $275
Current: $334.38
Upside: -17.76%
Oct 10, 2023
Maintains: Neutral
Price Target: $31 → $25
Current: $10.80
Upside: +131.48%
Jul 11, 2023
Maintains: Buy
Price Target: $48 → $50
Current: $21.20
Upside: +135.85%
Jul 11, 2023
Maintains: Neutral
Price Target: $80 → $76
Current: $60.68
Upside: +25.25%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $1.35
Upside: +4,122.22%